- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Aliskiren
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 39
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- IgAN, LN, MN, C3G
- Interventions
- OMS721 (narsoplimab)
- Biological
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
- Conditions
- Glomerulonephritis, Membranous, antiPLA2R Positive
- Interventions
- MOR202
- Drug
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Azusa, California • San Francisco, California • Torrance, California + 8 more
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Interventions
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
- Drug · Procedure
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
- Interventions
- Interview
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Nephrotic Syndrome, Membranous Nephropathy
- Interventions
- Apixaban 5 MG
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Treatment Resistant Nephrotic Syndrome
- Interventions
- ACTHAR gel
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Interventions
- Belimumab, Placebo for Belimumab, Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Zanubrutinib, Tacrolimus
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- budoprutug
- Drug
- Lead sponsor
- Climb Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 4 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- ALXN1920, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
- Conditions
- Membranous Nephropathy
- Interventions
- VB119
- Drug
- Lead sponsor
- Tenet Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Albany, New York • Bethlehem, Pennsylvania + 1 more
- Conditions
- SLE Glomerulonephritis Syndrome, WHO Class V
- Interventions
- Acthar gel
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Membranous Glomerulonephritis, Lupus Membranous Nepropathy
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- TRU-015
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
- Conditions
- Membranous Nephropathy
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Povetacicept, Tacrolimus
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 27
- States / cities
- Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 23 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
- Conditions
- Membranous Nephropathy
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Interventions
- Serum and renal tissue analysis
- Other
- Lead sponsor
- Meyer Children's Hospital IRCCS
- Other
- Eligibility
- 0 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Glomerular Disease
- Interventions
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Dietary Supplement
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more